Axsome Therapeutics Stock Current Valuation
| AXSM Stock | USD 67.90 2.18 3.32% |
Valuation analysis of Axsome Therapeutics helps investors to measure Axsome Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 19th of April 2024, Enterprise Value is likely to grow to about 3.6 B, while Enterprise Value Over EBITDA is likely to drop (20.37). Fundamental drivers impacting Axsome Therapeutics' valuation include:
Price Book 17.1536 | Enterprise Value 3.1 B | Enterprise Value Ebitda (13.67) | Price Sales 12.1062 | Enterprise Value Revenue 11.3678 |
Undervalued
Today
Please note that Axsome Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Axsome Therapeutics is based on 3 months time horizon. Increasing Axsome Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Axsome Therapeutics is useful when determining the fair value of the Axsome stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Axsome Therapeutics. Since Axsome Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Axsome Stock. However, Axsome Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 67.9 | Real 75.77 | Target 116.45 | Hype 65.8 |
The real value of Axsome Stock, also known as its intrinsic value, is the underlying worth of Axsome Therapeutics Company, which is reflected in its stock price. It is based on Axsome Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Axsome Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Axsome Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Axsome Therapeutics helps investors to forecast how Axsome stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Axsome Therapeutics more accurately as focusing exclusively on Axsome Therapeutics' fundamentals will not take into account other important factors: Axsome Therapeutics Company Current Valuation Analysis
Axsome Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Axsome Therapeutics Current Valuation | 3.1 B |
Most of Axsome Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Axsome Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Axsome Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Axsome Therapeutics is extremely important. It helps to project a fair market value of Axsome Stock properly, considering its historical fundamentals such as Current Valuation. Since Axsome Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Axsome Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Axsome Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Axsome Current Valuation Historical Pattern
Today, most investors in Axsome Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Axsome Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Axsome Therapeutics current valuation as a starting point in their analysis.
Axsome Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Axsome Therapeutics has a Current Valuation of 3.1 B. This is 78.4% lower than that of the Pharmaceuticals sector and 33.21% lower than that of the Health Care industry. The current valuation for all United States stocks is 81.34% higher than that of the company.
Axsome Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Axsome Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Axsome Therapeutics could also be used in its relative valuation, which is a method of valuing Axsome Therapeutics by comparing valuation metrics of similar companies.Axsome Therapeutics is currently under evaluation in current valuation category among related companies.
Axsome Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Axsome Therapeutics from analyzing Axsome Therapeutics' financial statements. These drivers represent accounts that assess Axsome Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Axsome Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.5B | 3.0B | 1.4B | 3.1B | 3.6B | 3.8B | |
| Enterprise Value | 3.3B | 2.9B | 1.4B | 3.0B | 3.4B | 3.6B |
Axsome Fundamentals
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (0.88) % | ||||
| Operating Margin | (0.78) % | ||||
| Current Valuation | 3.1 B | ||||
| Shares Outstanding | 47.37 M | ||||
| Shares Owned By Insiders | 17.12 % | ||||
| Shares Owned By Institutions | 83.33 % | ||||
| Number Of Shares Shorted | 7.65 M | ||||
| Price To Earning | (3.34) X | ||||
| Price To Book | 17.15 X | ||||
| Price To Sales | 12.11 X | ||||
| Revenue | 270.6 M | ||||
| Gross Profit | 45.94 M | ||||
| EBITDA | (176.07 M) | ||||
| Net Income | (239.24 M) | ||||
| Cash And Equivalents | 73.39 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 186.37 M | ||||
| Debt To Equity | 6.20 % | ||||
| Current Ratio | 2.44 X | ||||
| Book Value Per Share | 4.03 X | ||||
| Cash Flow From Operations | (145.08 M) | ||||
| Short Ratio | 8.86 X | ||||
| Earnings Per Share | (5.27) X | ||||
| Target Price | 123.0 | ||||
| Number Of Employees | 545 | ||||
| Beta | 1.1 | ||||
| Market Capitalization | 3.11 B | ||||
| Total Asset | 588.24 M | ||||
| Retained Earnings | (835.57 M) | ||||
| Working Capital | 365.41 M | ||||
| Current Asset | 34.76 M | ||||
| Current Liabilities | 6.74 M | ||||
| Net Asset | 588.24 M |
About Axsome Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Axsome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Axsome Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Axsome Stock
| 0.86 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.84 | ME | 23Andme Holding | PairCorr |
Moving against Axsome Stock
| 0.82 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
| 0.7 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.7 | DSGN | Design Therapeutics Downward Rally | PairCorr |
| 0.62 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
| 0.6 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.
The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Axsome Therapeutics Piotroski F Score and Axsome Therapeutics Altman Z Score analysis. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Axsome Stock analysis
When running Axsome Therapeutics' price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.27) | Revenue Per Share 5.957 | Quarterly Revenue Growth 1.935 | Return On Assets (0.25) | Return On Equity (1.59) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.